文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

正电子发射断层扫描与肺癌患者生存率的提高:重温威尔·罗杰斯现象

Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited.

作者信息

Chee Karen G, Nguyen Danh V, Brown Monica, Gandara David R, Wun Ted, Lara Primo N

机构信息

UC Davis Cancer Center, Sacramento, CA 95817, USA.

出版信息

Arch Intern Med. 2008 Jul 28;168(14):1541-9. doi: 10.1001/archinte.168.14.1541.


DOI:10.1001/archinte.168.14.1541
PMID:18663166
Abstract

BACKGROUND: The Will Rogers phenomenon occurs when newer technology allows for more sensitive detection of tumor spread, resulting in stage migration and an apparent improvement in patient survival. We investigated whether use of highly sensitive positron emission tomography (PET) scanning in non-small cell lung cancer has had this effect. METHODS: We performed a retrospective analysis involving 12,395 patients with non-small cell lung cancer in the pre-PET (1994-1998) and PET (1999-2004) periods. Interperiod differences in staging procedures, clinical variables, and patient survival were evaluated. RESULTS: There was a 5.4% decline in the number of patients with stage III disease and an 8.4% increase in the number of patients with stage IV disease in the PET period, corresponding with an increase in PET use from 6.3% to 20.1% (P < .001). The PET period predicted better survival with a hazard ratio (HR) of 0.95 (95% confidence interval [CI], 0.91-0.99) (P = .02). Use of PET was independently associated with better survival in patients with stage III (HR, 0.77; 95% CI, 0.69-0.85) and stage IV (HR, 0.64; 95% CI, 0.58-0.70) disease, but not those with stage I or II disease. CONCLUSION: These data support the notion that stage migration is responsible at least in part for an apparent improvement in survival for patients with stage III and IV non-small cell lung cancer in the PET scan era.

摘要

背景:当新技术能够更灵敏地检测肿瘤扩散时,就会出现威尔·罗杰斯现象,这会导致分期迁移以及患者生存率的明显改善。我们调查了在非小细胞肺癌中使用高灵敏度正电子发射断层扫描(PET)是否产生了这种效果。 方法:我们对1994 - 1998年PET前时期和1999 - 2004年PET时期的12395例非小细胞肺癌患者进行了回顾性分析。评估了分期程序、临床变量和患者生存率的时期间差异。 结果:在PET时期,III期疾病患者数量下降了5.4%,IV期疾病患者数量增加了8.4%,这与PET的使用从6.3%增加到20.1%相对应(P < 0.001)。PET时期预测生存率更好,风险比(HR)为0.95(95%置信区间[CI],0.91 - 0.99)(P = 0.02)。PET的使用与III期(HR,0.77;95% CI,0.69 - 0.85)和IV期(HR,0.64;95% CI,0.58 - 0.70)疾病患者的更好生存率独立相关,但与I期或II期疾病患者无关。 结论:这些数据支持这样一种观点,即分期迁移至少部分导致了PET扫描时代III期和IV期非小细胞肺癌患者生存率的明显改善。

相似文献

[1]
Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited.

Arch Intern Med. 2008-7-28

[2]
[Non-small cell lung carcinoma--Will Rogers phenomenon and better survival are jointly responsible].

Pneumologie. 2008-12

[3]
The effect of FDG-PET on the stage distribution of non-small cell lung cancer.

J Thorac Oncol. 2008-2

[4]
Does positron emission tomography scanning improve survival in patients undergoing potentially curative lung resections for non-small-cell lung cancer?

Eur J Cardiothorac Surg. 2011-2-20

[5]
Prognostic value of FDG uptake in early stage non-small cell lung cancer.

Eur J Cardiothorac Surg. 2008-5

[6]
The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival.

J Thorac Cardiovasc Surg. 2005-7

[7]
Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2003.

J Clin Oncol. 2012-7-2

[8]
Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.

J Clin Oncol. 2005-11-20

[9]
Does positron emission tomography prevent nontherapeutic pulmonary resections for clinical stage IA lung cancer?

Ann Thorac Surg. 2008-4

[10]
Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors.

Eur J Nucl Med Mol Imaging. 2007-1

引用本文的文献

[1]
Incidence and Dynamics of CRC Stage Migration: A Regional vs. a National Analysis.

Cancers (Basel). 2024-9-24

[2]
Investigating the influence of long-axial versus short-axial field of view PET/CT on stage migration in lymphoma and non-small cell lung cancer.

Nucl Med Commun. 2023-11-1

[3]
Changing Role of PET/CT in Cancer Care With a Focus on Radiotherapy.

Cureus. 2022-12-22

[4]
Classifying Oligometastatic Non-Small Cell Lung Cancer.

Cancers (Basel). 2021-9-27

[5]
Epidemiology and Survival Outcomes for Patients With NSCLC in Scandinavia in the Preimmunotherapy Era: A SCAN-LEAF Retrospective Analysis From the I-O Optimise Initiative.

JTO Clin Res Rep. 2021-3-24

[6]
The Will Rogers phenomenon, breast cancer and race.

BMC Cancer. 2021-5-17

[7]
Circulating miR-21-5p and miR-126-3p: diagnostic, prognostic value, and multivariate analysis in non-small-cell lung cancer.

Mol Biol Rep. 2021-3

[8]
Why Has Breast Cancer Screening Failed to Decrease the Incidence of de Novo Stage IV Disease?

Cancers (Basel). 2019-4-8

[9]
Pretreatment metabolic tumour volume in stage IIIA/B non-small-cell lung cancer uncovers differences in effectiveness of definitive radiochemotherapy schedules: analysis of the ESPATUE randomized phase 3 trial.

Eur J Nucl Med Mol Imaging. 2019-2-1

[10]
Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer.

J Clin Med. 2019-1-23

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索